LT3662910T - Trail geno indukcijai skirtas farmakoforas - Google Patents

Trail geno indukcijai skirtas farmakoforas

Info

Publication number
LT3662910T
LT3662910T LTEP19218049.5T LT19218049T LT3662910T LT 3662910 T LT3662910 T LT 3662910T LT 19218049 T LT19218049 T LT 19218049T LT 3662910 T LT3662910 T LT 3662910T
Authority
LT
Lithuania
Prior art keywords
pharmacophore
gene induction
trail gene
trail
induction
Prior art date
Application number
LTEP19218049.5T
Other languages
English (en)
Inventor
Kim D Janda
Nicholas T. JACOB
Jonathan W. LOCKNER
Original Assignee
The Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Scripps Research Institute filed Critical The Scripps Research Institute
Publication of LT3662910T publication Critical patent/LT3662910T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP19218049.5T 2014-03-31 2015-03-30 Trail geno indukcijai skirtas farmakoforas LT3662910T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461972689P 2014-03-31 2014-03-31

Publications (1)

Publication Number Publication Date
LT3662910T true LT3662910T (lt) 2024-12-27

Family

ID=54241169

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP19218049.5T LT3662910T (lt) 2014-03-31 2015-03-30 Trail geno indukcijai skirtas farmakoforas
LTEP15772254.7T LT3125898T (lt) 2014-03-31 2015-03-30 Farmakoforas, skirtas trail indukcijai

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP15772254.7T LT3125898T (lt) 2014-03-31 2015-03-30 Farmakoforas, skirtas trail indukcijai

Country Status (20)

Country Link
US (5) US10239877B2 (lt)
EP (3) EP3125898B1 (lt)
JP (4) JP6756435B2 (lt)
KR (2) KR102473930B1 (lt)
CN (2) CN111499636B (lt)
AU (4) AU2015241069B2 (lt)
CA (2) CA3158795A1 (lt)
CY (1) CY1123093T1 (lt)
DK (2) DK3125898T3 (lt)
ES (2) ES2999685T3 (lt)
FI (1) FI3662910T3 (lt)
HR (2) HRP20200478T1 (lt)
HU (2) HUE069651T2 (lt)
LT (2) LT3662910T (lt)
PL (2) PL3662910T3 (lt)
PT (2) PT3125898T (lt)
RS (2) RS66254B1 (lt)
SI (2) SI3662910T1 (lt)
SM (2) SMT202000219T1 (lt)
WO (1) WO2015153468A1 (lt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014160130A1 (en) 2013-03-13 2014-10-02 Oncoceutics, Inc. Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
US9688679B2 (en) 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
IL311202A (en) * 2013-11-15 2024-05-01 Oncoceutics Inc 7-Benzyl-4-(2-methylbenzyl)-2, 4, 6, 7, 8, 9-hexahydroimidazo [1,2-A] pyrido[3,4-E] pyrimidine-5(1H)one, its salts and methods Use
LT3662910T (lt) 2014-03-31 2024-12-27 The Scripps Research Institute Trail geno indukcijai skirtas farmakoforas
WO2016123571A1 (en) * 2015-01-30 2016-08-04 Oncoceutics Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs and salts thereof and their use in therapy
CN104860948B (zh) 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
PL3408298T3 (pl) * 2016-01-29 2025-03-31 Oncoceutics, Inc. Modulacja przez imiprydony receptora sprzężonego z białkiem g (gpcr)
WO2018031987A1 (en) 2016-08-12 2018-02-15 Nanjing Gator Meditech Company, Ltd. Protein kinase regulators
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
GB2596010B (en) * 2019-02-11 2023-03-01 Madera Therapeutics Llc Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents
AU2020228047B2 (en) 2019-02-27 2025-11-20 Madera Therapeutics, LLC Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents
MX2023001576A (es) 2020-08-06 2023-05-09 Eoetvoes Lorand Tudomanyegyetem Síntesis de nuevos derivados de imipridona y su evaluación de su actividad anticáncerigena.
CN115448921B (zh) * 2021-06-08 2023-08-01 四川大学 一类咪唑烷并嘧啶酮化合物及在治疗HsClpP介导的疾病中的用途
CN116751199B (zh) * 2023-06-02 2025-03-18 中国科学院基础医学与肿瘤研究所(筹) 一种线粒体蛋白酶靶向嵌合体、制备方法及用途
EP4684834A1 (de) * 2024-07-26 2026-01-28 BRIU GmbH Kristallformen onkologisch wirksamer imipridone und verfahren zu deren herstellung

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE786028A (fr) * 1971-07-08 1973-01-08 Boehringer Sohn Ingelheim 2,3-dihydro-oxo-imidazo(1,2-a)-pyrimidines, leurs sels d'addition avec des acides et procedes pour les fabriquer
DE2150062A1 (de) 1971-10-07 1973-04-12 Boehringer Sohn Ingelheim Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung
JPS5374893A (en) 1976-12-15 1978-07-03 Fujitsu Ltd Driving method for semiconductor photosensitive device
JPS6132833U (ja) 1984-07-31 1986-02-27 日信工業株式会社 デイスクブレ−キ装置
WO2004039774A2 (en) * 2002-05-23 2004-05-13 Merck & Co., Inc. Mitotic kinesin inhibitors
PL2303264T3 (pl) * 2008-06-09 2018-08-31 Allergan, Inc. Sposoby leczenia stanów pośredniczonych alfa-adrenergicznie z użyciem pochodnych imidazoliny
AU2011239537A1 (en) * 2010-04-16 2012-11-15 Curis, Inc. Treatment of cancers having K-ras mutations
WO2012078448A1 (en) * 2010-12-06 2012-06-14 Schering Corporation Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
UA113508C2 (xx) * 2011-03-15 2017-02-10 Ізоксазолідинові похідні
EP2694678A2 (en) * 2011-04-04 2014-02-12 Netherland Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
FI4335511T3 (fi) 2011-04-29 2026-01-29 Penn State Res Found Pienimolekyylinen normaalien ja kasvainsolujen trail-geenin indusointi syöpähoitona
US9688679B2 (en) 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
WO2014160130A1 (en) * 2013-03-13 2014-10-02 Oncoceutics, Inc. Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one
WO2015073072A1 (en) * 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
US9181237B2 (en) * 2013-10-04 2015-11-10 Mallinckrodt Llc Substituted berbines and their synthesis
LT3662910T (lt) 2014-03-31 2024-12-27 The Scripps Research Institute Trail geno indukcijai skirtas farmakoforas

Also Published As

Publication number Publication date
FI3662910T3 (fi) 2024-10-31
US20220002300A1 (en) 2022-01-06
LT3125898T (lt) 2020-04-10
EP3662910A1 (en) 2020-06-10
ES2999685T3 (en) 2025-02-26
CA2944452C (en) 2022-07-19
PT3125898T (pt) 2020-04-01
US20200283440A1 (en) 2020-09-10
EP3662910B1 (en) 2024-09-18
EP4470617A3 (en) 2025-02-26
EP3125898A4 (en) 2017-08-16
CY1123093T1 (el) 2021-10-29
JP2021119157A (ja) 2021-08-12
CA2944452A1 (en) 2015-10-08
US10633385B2 (en) 2020-04-28
SI3662910T1 (sl) 2025-05-30
JP7186256B2 (ja) 2022-12-08
CN111499636B (zh) 2023-01-13
JP2023022184A (ja) 2023-02-14
HRP20200478T1 (hr) 2020-07-24
US20240190877A1 (en) 2024-06-13
AU2024204977A1 (en) 2024-08-08
KR102473930B1 (ko) 2022-12-05
US20190284188A1 (en) 2019-09-19
HRP20241680T1 (hr) 2025-02-28
SMT202000219T1 (it) 2020-05-08
US10239877B2 (en) 2019-03-26
AU2024204977B2 (en) 2026-04-16
DK3662910T3 (en) 2024-11-04
HUE049013T2 (hu) 2020-08-28
PL3662910T3 (pl) 2025-08-11
JP6756435B2 (ja) 2020-09-16
KR20160138513A (ko) 2016-12-05
KR102611067B1 (ko) 2023-12-06
RS60163B1 (sr) 2020-05-29
AU2015241069A1 (en) 2016-10-20
US20170107221A1 (en) 2017-04-20
CA3158795A1 (en) 2015-10-08
JP2017511321A (ja) 2017-04-20
EP3125898A1 (en) 2017-02-08
SI3125898T1 (sl) 2020-07-31
AU2022283729A1 (en) 2023-02-02
WO2015153468A1 (en) 2015-10-08
PT3662910T (pt) 2024-11-27
SMT202400497T1 (it) 2025-01-14
JP6873201B2 (ja) 2021-05-19
RS66254B1 (sr) 2024-12-31
HUE069651T2 (hu) 2025-03-28
PL3125898T3 (pl) 2020-11-16
AU2020286314A1 (en) 2021-01-21
ES2779979T3 (es) 2020-08-21
JP2020002170A (ja) 2020-01-09
CN111499636A (zh) 2020-08-07
AU2015241069B2 (en) 2020-10-15
JP7688245B2 (ja) 2025-06-04
KR20220163533A (ko) 2022-12-09
US11891392B2 (en) 2024-02-06
DK3125898T3 (da) 2020-03-30
CN106456643A (zh) 2017-02-22
CN106456643B (zh) 2020-04-17
EP4470617A2 (en) 2024-12-04
EP3125898B1 (en) 2019-12-25

Similar Documents

Publication Publication Date Title
LT3662910T (lt) Trail geno indukcijai skirtas farmakoforas
DK3102669T3 (da) Forbedret bacillevært
DK3233887T3 (da) Immunmodulatorer
PL3118311T3 (pl) Antysensowny kwas nukleinowy
HUE057846T2 (hu) Permanens epigenetikus géncsendesítés
HUE042335T2 (hu) ROR-gamma dihidropirrolopiridin inhibitorai
DK3188836T3 (da) Dna-syntese
DK3102722T3 (da) Genom fraktionering
MA39481A (fr) Thérapies ciblées
HUE054784T2 (hu) 5-klór-2-difluor-metoxifenil-pirazolopirimidin vegyületek, amelyek JAK-gátlók
HUE054514T2 (hu) Kemence
HUE042087T2 (hu) Inhalátor
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
FR3025617B1 (fr) Architecture bi-voies
IL249254A0 (en) Gene expression system
EP3125821C0 (en) INSERT FOR AN INHALER
IL252086A0 (en) Novel methods
IL257500A (en) Altered cullin1 gene
LT3628731T (lt) Naujas antipresepsino antikūnas
SG11201609108TA (en) Antibody gene expression-secretion system
EP2993051A4 (en) PRINTER
BR112017008675A2 (pt) impressoras
ES1135593Y (es) Multibotella
UA28521S (uk) Наличка
ES1122680Y (es) Ladrillo caravista